Renaissance Technologies's MDGL Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 120,682 shares of Madrigal Pharmaceuticals, Inc. (MDGL) worth $55.35 M, representing 0.07% of the portfolio. First purchased in 2016-Q3, this long-term strategic position has been held for 37 quarters.
Based on 13F filings, Renaissance Technologies has maintained a strategic position in MDGL, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2023, adding 170,800 shares. Largest reduction occurred in Q2 2023, reducing 96,700 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's Madrigal Pharmaceuticals (MDGL) Holding Value Over Time
Track share changes against reported price movement
Quarterly Madrigal Pharmaceuticals (MDGL) Trades by Renaissance Technologies
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2016 | +52,987 | New Buy | 52,987 | $12.68 |
| Q4 2016 | +4,488 | Add 8.47% | 57,475 | $14.89 |
| Q1 2017 | +400 | Add 0.70% | 57,875 | $15.40 |
| Q2 2017 | +17,512 | Add 30.26% | 75,387 | $16.26 |
| Q3 2017 | +51,900 | Add 68.84% | 127,287 | $44.98 |
| Q4 2017 | -39,700 | Reduce 31.19% | 87,587 | $91.79 |
| Q1 2018 | -87,587 | Sold Out | 87,587 | $0.00 |
| Q1 2020 | +26,482 | New Buy | 26,482 | $66.76 |
| Q2 2020 | +45,900 | Add 173.33% | 72,382 | $113.25 |
| Q3 2020 | -50,600 | Reduce 69.91% | 21,782 | $118.72 |
| Q4 2020 | +12,251 | Add 56.24% | 34,033 | $111.16 |
| Q1 2021 | +249 | Add 0.73% | 34,282 | $116.97 |
| Q2 2021 | +18,700 | Add 54.55% | 52,982 | $97.41 |
| Q3 2021 | -35,871 | Reduce 67.70% | 17,111 | $79.77 |
| Q4 2021 | -14,711 | Reduce 85.97% | 2,400 | $84.58 |
| Q1 2022 | +2,400 | Add 100.00% | 4,800 | $98.12 |
| Q2 2022 | -4,800 | Sold Out | 4,800 | $0.00 |
| Q4 2022 | +4,582 | New Buy | 4,582 | $0.29 |
| Q1 2023 | +170,800 | Add 3727.63% | 175,382 | $0.24 |
| Q2 2023 | -96,700 | Reduce 55.14% | 78,682 | $0.23 |
| Q3 2023 | -10,600 | Reduce 13.47% | 68,082 | $146.04 |
| Q4 2023 | -68,082 | Sold Out | 68,082 | $0.00 |
| Q3 2024 | +44,497 | New Buy | 44,497 | $212.22 |
| Q4 2024 | +116,285 | Add 261.33% | 160,782 | $308.57 |
| Q1 2025 | -75,696 | Reduce 47.08% | 85,086 | $331.23 |
| Q2 2025 | -74,250 | Reduce 87.26% | 10,836 | $302.64 |
| Q3 2025 | +109,846 | Add 1013.71% | 120,682 | $458.66 |
Renaissance Technologies's Madrigal Pharmaceuticals Investment FAQs
Renaissance Technologies first purchased Madrigal Pharmaceuticals, Inc. (MDGL) in Q3 2016, acquiring 52,987 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held Madrigal Pharmaceuticals, Inc. (MDGL) for 37 quarters since Q3 2016. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies's largest addition to Madrigal Pharmaceuticals, Inc. (MDGL) was in Q1 2023, adding 175,382 shares worth $42,488. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 120,682 shares of Madrigal Pharmaceuticals, Inc. (MDGL), valued at approximately $55.35 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Madrigal Pharmaceuticals, Inc. (MDGL) represents approximately 0.07% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies's peak holding in Madrigal Pharmaceuticals, Inc. (MDGL) was 175,382 shares, as reported at the end of Q1 2023. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.